[Omapatrilat for treatment of heart failure].
Yamazaki
Tsutomu
T
Department of Clinical Bioinformatics, Graduate School of Medicine, The University of Tokyo.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D023381:Endpoint Determination; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D015996:Survival Rate; D013841:Thiazepines / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011480:Protease Inhibitors; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; D015260:Neprilysin